Chemoprevention and Therapeutic Treatment of Brca1 Associated Breast Cancer in Conditional Knockout Mice

Yohei Tominaga,Joseph A. De Soto,Rui-Hong Wang,Chu-Xia Deng

IF: 11.2

2006-01-01

Cancer Research

Abstract:679 Germline mutations of the breast cancer associated gene 1 (BRCA1) have been identified in about 50% of familial breast cancer cases and about 90% of familial breast and ovarian cancers. BRCA1 mutation carriers have a 50 to 80% lifetime risk for developing breast cancer by age 70. Current screening and chemoprevention strategies are suboptimal and consequently some women who are BRCA1 gene carriers elect to prophylactically have their breasts and/or ovaries removed to reduce their risk. Moreover, current chemopreventative drugs often give adverse effects, primarily due to poor specificity of the compounds to mammary tumor tissues. Thus, there is an urgent need to develop safe and effective drugs for the chemoprevention and therapeutic treatment of breast cancer. In the past years, we have created a mouse model carrying a tissue specific disruption of BRCA1 in mammary epithelium. The mutant mice developed mammary tumors at 7-12 months of age. Our analysis revealed that the tumor progression is accompanied by extensive genetic instability and alteration of a number of oncogenes and tumor suppressor genes. Using this animal model and cell lines derived from mammary tumors, we have been studying effects of genistein, green tea, resveratrol, and Poly(ADP-ribose) polymerase (PARP1) inhibitors on BRCA1-associcated tumor formation in order to provide better understand and therapeutic options of BRCA1-assicated breast cancer. Our study indicated that both genistein and resveratrol inhibit growth of tumor cells in culture, in soft agar colony formation and in an allograft nude mouse model. Genistein treated BRCA1 mutant cells were highly polypoid and displayed extensive chromosome abnormalities. Western blot analysis revealed significant increase of CHK2 phosphorylation upon genistein treatment. These observations suggest that genistein induced activation of cell cycle inhibitors may cause cell cycle arrest and cell death, which account for the reduced growth of mutant cells upon the drug treatment. We found that the apoptosis induced by resveratrol in the tumors is accompanied by the activation of NF-kB pathway, and is also partially due to the activation of CHK2 in DNA damage response. Of note, we failed to detect any preventive or therapeutic effects of green tea in both allograft and BRCA1 conditional animals tested. The effectiveness of PARP-1 inhibitors also seemed more specific to BRCA1 mutant embryonic stem cells rather than BRCA1 mutant mammary tumor cells. These data, although promising, remain to be tested in human BRCA1 associated breast cancer cells. Our long-term goal is to decrease cancer risk of BRCA-mutation carriers and find a safe and effective therapeutic method to cure this disease.